

Review

Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations

Stephen Byrn,^{1,4} Ralph Pfeiffer,¹ Michael Ganey,^{2,3} Charles Hoiberg,² and Guirag Poochikian²

Purpose. This review describes a conceptual approach to the characterization of pharmaceutical solids. **Methods.** Four flow charts are presented: (1) polymorphs, (2) hydrates, (3) desolvated solvates, and (4) amorphous forms. **Results.** These flow charts (decision trees) are suggested as tools to develop information on pharmaceutical solids for both scientific and regulatory purposes. **Conclusions.** It is hoped that this review will lead to a more direct approach to the characterization of pharmaceutical solids and ultimately to faster approval of regulatory documents containing information on pharmaceutical solids.

KEY WORDS: polymorph; hydrate; amorphous form; desolvated solvate.

Interest in the subject of pharmaceutical solids stems in part from the Food and Drug Administration's (FDA's) drug substance guideline that states "appropriate" analytical procedures should be used to detect polymorphic, hydrated, or amorphous forms of the drug substance. These guidelines suggest the importance of controlling the crystal form of the drug substance. The guideline also states that it is the applicant's responsibility to control the crystal form of the drug substance and, if bioavailability is affected, to demonstrate the suitability of the control methods.

Thus, while it is clear that the New Drug Application (NDA) should contain information on solid state properties, particularly when bioavailability is an issue, the applicant may be unsure about how to scientifically approach the gathering of information and perhaps what kind of information is needed. This review is intended to provide a strategic approach to remove much of this uncertainty by presenting concepts and ideas in the form of flow charts rather than a set of guidelines or regulations. This is especially important because each individual compound has its own peculiarities which require flexibility in approach. The studies proposed herein are part of the Investigational New Drug (IND) process.

Solid drug substances display a wide and largely unpredictable variety of solid state properties. Nevertheless, application of basic physicochemical principles combined with appropriate analytical methodology can provide a strategy

for scientific and regulatory decisions related to solid state behavior in the majority of cases. By addressing *fundamental* questions about solid state behavior at an early stage of drug development, both the applicant and the FDA are in a better position to assess the possible effects of any variations in the solid state properties of the drug substance. The resulting early interaction of the parties with regard to this area would not only tend to ensure uniformity of the materials used throughout the clinical trials but also fully resolve solid state issues before the critical stages of drug development. A further benefit of these scientific studies is the development of a meaningful set of solid state specifications which critically describe the solid form of the drug substance. These specifications would thus also facilitate the approval of a change in supplier or chemical process.

Our approach in this review is to suggest a sequence for collecting data on a drug substance that will efficiently answer specific questions about solid state behavior in a logical order. In "difficult" cases, perhaps where mixtures of forms must be dealt with, or other unusual properties are encountered, the suggested sequences would still have to be followed as a first stage in this investigation.

We have chosen to present this approach in the form of a series of decision trees, or flow charts (algorithms), one for each of the most common solid state forms. The charts are accompanied by examples from the literature representing the kind of data that would be useful in supporting the various decisions.

Decision trees provide conceptual frameworks for understanding how the justification for different crystal forms might be presented in the drug application. Industry may wish to use these decision trees as a strategic tool to organize the gathering of information early in the drug development process. Put another way, these decision trees provide a thought process that will lead to development of the most

¹ Department of Medicinal Chemistry and Pharmacognosy, Purdue University, West Lafayette, Indiana 47907.

² Division of Oncology and Pulmonary, Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20857.

³ Current Address: Pfizer Central Research, Groton, Connecticut.

⁴ To whom correspondence should be addressed.

appropriate analytical controls. One should also note that it is the responsibility of the industry to select the appropriate test or tests to identify the phase of the solid and determine its relevant pharmaceutical properties. This approach is superior to simply performing a broad range of tests without regard to their relevance.

We should point out that, from a regulatory standpoint, if a company can establish a specification/test to ensure production of a well defined solid form of the drug substance, then it is not necessary to do all of the physical/chemical testing outlined in the decision trees. From a scientific standpoint, however, such an approach is risky since new forms may appear unpredictably during various stages of the development process. The appearance of these new forms usually slows the drug approval process and makes planning difficult.

Four decision trees are described in the sections that follow: Polymorphs; Hydrates (Solvates); Desolvated Solvates; and Amorphous Forms. Polymorphs exist when the drug substance crystallizes in different crystal packing arrangements all of which have the same elemental composition (Note that hydrates can exist in polymorphs). Hydrates exist when the drug substance incorporates water in the crystal lattice in either stoichiometric or non-stoichiometric amounts. Desolvated solvates are produced when a solvate is desolvated (either knowingly or unknowingly) and the crystal retains the structure of the solvate. Amorphous forms exist when a solid with no long range order and thus no crystallinity is produced. It is apparent that the appropriate flow chart can only be determined after the solid has been characterized using some of the tests described in the first decision point of the decision trees/flow charts (i.e. X-ray powder diffraction, elemental analysis, etc.). If there is no interest in marketing or producing an amorphous form or desolvated solvate at any stage in the process, then the corresponding flow charts do not need to be addressed. As already mentioned, it is advisable to investigate the drug substance for the existence of polymorphs and hydrates since these may be encountered at any stage of the drug manufacturing process or upon storage of the drug substance or dosage form.

All of the flow charts end (see for example Figure 1) with an indication of the types of controls which will be required based on whether a single morphic form or a mixture will be produced as the drug substance. Although this ending provides a simplistic view of a very complicated process of selecting appropriate controls, it is included to illustrate the consequence of the decisions made with regard to the drug substance. The reader should realize that the actual selection of the appropriate control could be the subject of another review which might contain another set of flow charts or decision trees.

POLYMORPHS

The flow chart/decision tree for polymorphs is shown in Figure 1. It outlines investigations of the formation of polymorphs, the analytical tests available for identifying polymorphs, studies of the physical properties of polymorphs and the controls needed to ensure the integrity of drug substance containing either a single morphic form or a mixture.

A. Formation of Polymorphs—Have Polymorphs Been Discovered?

The first step in the polymorphs decision tree is to crystallize the substance from a number of different solvents in order to attempt to answer the question: Are polymorphs possible? Solvents should include those used in the final crystallization steps and those used during formulation and processing and may also include water, methanol, ethanol, propanol, isopropanol, acetone, acetonitrile, ethyl acetate, hexane and mixtures if appropriate. New crystal forms can often be obtained by cooling hot saturated solutions or partly evaporating clear saturated solutions. The solids produced are analyzed using X-ray diffraction and at least one of the other methods. In these analyses, care must be taken to show that the method of sample preparation (i.e. drying, grinding) has not affected the solid form. If the analyses show that the solids obtained are identical (e.g. have the same X-ray diffraction patterns and IR spectra) then the answer to the question "Are polymorphs possible?" is "No",




Figure 1. Flow chart/decision tree for polymorphs.

and further research is not needed. The work of Miyamae *et al.* serves as a good example of solid state studies of a drug substance which exists as polymorphs (1). Powder diffraction showed that there were two crystal forms (see Figure 2).

These workers also carried out single crystal analysis of the two crystal forms of the compound. The structures are shown in Figure 3. While such studies are not required, and indeed sometimes not possible, they provide an unequivocal confirmation of the existence of polymorphs. Moreover, once the single crystal structure of a phase has been determined, it is possible to calculate the corresponding X-ray powder pattern. This provides an irrefutable standard for identifying the phase by that method.

The DSC thermal curves of the two forms are slightly different, as shown in Figure 4 and thus may not be the preferred way of differentiating these polymorphs.

The IR spectra of the two polymorphs are quite similar(1), and IR does not appear to be a powerful method for differentiating the crystal forms in this case. Thus, for 8-(2-methoxycarbonylamino-6-methylbenzyloxy)-2-methyl-3-(2-propynyl)-imidazo{1,2-a}pyridine, powder diffraction appears to be the best method for differentiating the two forms.

Solid-state NMR is another powerful technique for analyzing different crystal forms (2,3). Figure 5 shows the solid-state C-13 NMR spectra of Forms I and II of prednisolone. Differences in the positions of the two resonances in the 120 ppm range clearly differentiate the two forms. In principle, solid state NMR is an absolute technique in which the signal intensity is proportional to the number of nuclei provided appropriate conditions are met. In addition, solid state NMR is a bulk technique which is not very sensitive to surface changes. This method appears to be very sensitive and will undoubtedly be used more often in the future as a tool to detect different crystal forms. However, with present technology, errors in solid-state quantitative studies may be rather large.




Figure 2. Powder X-ray diffraction patterns of the polymorphs of 8-(2-methoxycarbonylamino-6-methylbenzyloxy)-2-methyl-3-(2-propynyl)-imidazo{1,2-a}pyridine (1).




Figure 3. Stereoscopic drawings of the crystal packing of both polymorphs of 8-(2-methoxycarbonylamino-6-methylbenzyloxy)-2-methyl-3-(2-propynyl)-imidazo{1,2-a}pyridine viewed along the shortest axis (Form A, b-axis; Form B, a-axis) (1).

B. Do the Polymorphs Have Different Physical Properties?

If polymorphs exist then it is necessary to examine the physical properties of the different polymorphs that can affect dosage form performance (bioavailability and stability) or manufacturing reproducibility. The properties of interest are solubility profile (intrinsic dissolution rate, equilibrium solubility), stability (chemical and physical), and crystal morphology (including both shape and particle size), calorimetric behavior, and %RH profile. If there are no discernible differences between these physico-chemical properties, then the answer to the second question in the decision tree, "Different physical properties?" is "No."

The variable physical properties of several drugs with different polymorphs are reported in the literature. For example, the dissolution profiles of the polymorphs of chloramphenicol are significantly different (4). In addition, van't Hoff solubility analysis has been used to elucidate the dif-




Figure 4. DSC thermal curves of the polymorphs of 8-(2-methoxycarbonylamino-6-methylbenzyloxy)-2-methyl-3-(2-propynyl)-imidazo{1,2-a}pyridine (1). These curves show that Form A melts whereas Form B undergoes a small endothermic transition and then melts at the same temperature as Form A.




Figure 5. Solid state NMR of the two Crystal Forms of Prednisolone (2).

ferent solubilities of two polymorphs of methyl prednisolone(5). This method involves determining the equilibrium solubility of each polymorph at various temperatures. The log of the equilibrium solubility is then plotted vs $1/T$. This should give straight lines for each polymorph and the temperature at which the curves intersect is the transition temperature. This technique does not work if the polymorphs interconvert.

For balance, it is important to point out that there are also cases where polymorphs exist but they have virtually identical dissolution properties(6).

C. Drug Substance Control

The important question lies in the properties that differ among polymorphs and whether those properties affect the dosage form performance (i.e., quality or bioavailability). If they do then from a regulatory standpoint it is appropriate to establish a specification/test (e.g. powder X-ray diffraction or IR) to ensure the proper form is produced. From a production standpoint, it is important to develop a process that reproducibly produces the desired polymorph.

If mixtures of forms cannot be avoided, then quantitative control is needed to ensure that a fixed proportion of forms is obtained. Furthermore, the method of analyzing for the proportion of forms would have to be validated. Also, the proportion of forms would have to remain within stated limits through the retest date of the drug substance and potentially throughout the shelf life of the product; a difficult requirement if the forms interconvert. Thus, the way to avoid a substantial amount of work in this area is to select a single

solid form for production. Usually, this would be the most physically stable form when their bioavailabilities are not significantly different. Selection of the most stable form would, of course, insure that it there would be no conversion into other forms.

Powder diffraction is often a useful method to determine the percentages of polymorphs in a mixture; however, the detection limit is variable from case to case and can be as high as 15%. Matsuda (7) carried out a mixture analysis of phenylbutazone polymorphs. Diffraction lines disappear and appear as the ratio of the crystal forms change. Some of these calibration curves developed from this analysis are almost horizontal, meaning that any given mixture gives the same line intensity in this mixture range. However, other calibration curves are sloped and would appear to allow a reasonable analysis. It is fair (although Matsuda did not carry out an estimate) to estimate the errors in this analysis as $\pm 15\%$.

Tanninen and Ylirussi (8) used computer curve fitting to carry out a mixture analysis of prazosin. In this particular case, they reported a highly accurate analysis, and, in fact, showed a calibration curve that could detect 0.5% of one form in another. This is obviously a highly accurate mixture analysis by powder diffraction and shows the power of this method for some applications. However, this analysis required extreme care in sample preparation and may be more difficult to carry out in a production setting where particle size may not be controlled. Similar comments apply to the analysis of mixtures by IR, where the accuracy and precision may also vary considerably from case to case. Given the analytical problems in dealing with mixtures of forms, it may generally be simpler to develop a method to prepare only one crystal form.

In summary, it is important to determine whether polymorphs are present and to solve any problems before pivotal clinical studies are initiated.

D. Determination of the Polymorph Present in the Drug Product

In cases where stability or bioavailability issues exist, the solid form present in the drug product should be investigated, if possible.

For bulk drug substances, X-ray powder diffraction and other techniques can identify the polymorph; however, solid state NMR appears to be the best method for the study of the drug substance in the dosage form (2, 3). Solid-state NMR study of three commercial products containing prednisolone showed that the products A and B contain Form I, whereas product C contains Form II.. This analysis was possible even though these tablets contain approximately 95 mg of excipients and 5 mg of drug. There are numerous cases, often involving complex mixtures or low dose products, where solid state NMR (and, in fact, any technique) will not be sensitive enough to identify the polymorph present in the drug product. However, the safety and efficacy is, of course, controlled by the potency assays and by the physical tests (e.g., dissolution).

HYDRATES (SOLVATES)

The flow chart/decision tree for hydrates (solvates) is shown in Figure 6. It outlines investigations of the formation

HYDRATES (SOLVATES) Drug Substance and Solvent




Figure 6. Flow chart for solvates or hydrates.

of hydrates (solvates), the analytical tests available for hydrates (solvates), studies of the physical properties of hydrates (solvates) and the controls needed to ensure the integrity of drug substance containing either a single morphic form or a mixture.

A. Have Hydrates (Solvates) Been Discovered?

The flow chart for hydrates (solvates) (Figure 7) is applied after the preliminary crystallizations have been completed. These are essentially the same as in the polymorph decision tree but, in addition, should include solvent-water mixtures in order to maximize the chance for hydrate formation. These experiments can be guided by the moisture uptake (% RH) studies. Any solids that indicate a significant change in water content as indicated by the % RH-moisture profile should also be examined. The resulting solid phases are preferably characterized by a combination of methods—two for phase identity and two to reveal composition and stoichiometry.

With a very few exceptions, the structural solvent contained in marketed crystalline drug products is water. It is nevertheless often desirable to characterize other solvated crystalline forms of a drug for several reasons: they may be the penultimate form used to crystallize the final product and thus require controlled characterization; they may form if the final crystallization from solvents, especially mixed solvents, is not well controlled; they may be the actual crystallized form of a final product that is desolvated during a final drying step; they may be the form used in recovery for subsequent rework. The relevance of these points will vary from case to case, but for the present discussion we shall treat the subject of solvates in its broadest form.

Examples taken from the literature serve to illustrate the kind of data that proves useful in characterizing solvated crystal forms. For example, a recent report from our laboratory showed that IR and solid state NMR was useful for the identification of the different crystal forms of dirithromycin(9). TGA is another powerful method for the analysis

of solvates. For example, one early study showed that TGA could differentiate three different hydrated salts of fenoprofen(10). Combined with IR or other methods, TGA is an unequivocal method for the verification of the existence of solvates. In addition, TGA is a good method for looking at mixtures of solvated and unsolvated crystal forms, and probably can be developed into an analytical method for determining the ratios of solvated and unsolvated forms.

DSC is also a good method for detecting solvates since there is usually heat change involved in desolvation, especially for hydrates(11). Specifically, DSC by itself does not prove the existence of a solvate, but once other analytical




Figure 7. Water uptake vs percent relative humidity for sodium cefazolin.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.